Abstract 3493: Expression of VEGFR and FRGFR on Endothelial Cells Isolated from Hepatocellular Carcinoma and Adjacent Liver Tissue

Sun Hui-Chuan,Ling-Qun Kong,Xiao-Dong Zhu,Zong-Tao Chai,Wen-Quan Wang,Wei-Zhong Wu
DOI: https://doi.org/10.1158/1538-7445.am2011-3493
IF: 11.2
2011-01-01
Cancer Research
Abstract:Background Heterogenity in gene expression profiles in tumor endothelial cells (TEC) has been reported reported. Our previous studies showed TEC is also different from endothelial cells isolated from adjacent normal liver tissue (NEC) in term of response to chemotherapeutics and anti-angiogenesis drugs. Methods TEC and NEC were isolated by CD31 and CD105 antibody conjuaged magnetic beads from tumor and adjacent nontumor liver tissues from 5 patients who were diagnosed as hepatocellular carcinoma with a positive alpha fetoprotein (> 20ng/ml). The purity of ECs was proved by LDL internalization assay, tube formation, immunostaining and RT-PCR to exclude tumor cell contamination. VEGFR1, VEGFR2, FGFR-2, CD31 and CD105 expression on the isolated ECs were assayed by flow cytometry within 3-5 passages. Response of different types of ECs to sorafenib treatment was observed, including cell proliferation, VEGFRs and FGFR expression. Results The isolated ECs were proved by tumor formation and LDL internalization. More than 97% cells are LDL positive. AFP was not detectable on the isolated ECs in both flow cytometry assay and immunostaining assay. VEGFRs and FGFR expression were different on CD105+TEC and CD31+TEC among different patients, ranging from 18% to 67% for VEGFR1, 1% to 8% for VEGFR2, and 18% to 25% for FGFR-2 on CD105+TEC, and 18% to 90% for VEGFR1, 10% to 40% for VEGFR2, and 18% to 30% for FGFR-2 on CD31+TEC. Expression of VEGFRs and FGFR is higher on CD105+ECs than those on CD31+ECs. While between TEC and NEC, the expression of VEGFRs and FGFR is also heterogeneous. Sorafenib at 5 mM inhibted proliferation of TEC and NEC in a dose-dependent manner, while NEC is more sensitive to sorafenib treatment. Conclusions VEGFRs and FGFR expression were different among different patients; CD105+EC and CD31+EC are probably two types of ECs with different biological features. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3493. doi:10.1158/1538-7445.AM2011-3493
What problem does this paper attempt to address?